58 related articles for article (PubMed ID: 12717416)
1. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Zhou C; Smith JL; Liu J
Oncogene; 2003 Apr; 22(16):2396-404. PubMed ID: 12717416
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.
Ismail T; Alzneika S; Riguene E; Al-Maraghi S; Alabdulrazzak A; Al-Khal N; Fetais S; Thanassoulas A; AlFarsi H; Nomikos M
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543119
[TBL] [Abstract][Full Text] [Related]
4. A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
Alkailani M; Palidwor G; Poulin A; Mohan R; Pepin D; Vanderhyden B; Gibbings D
NAR Cancer; 2021 Mar; 3(1):zcaa040. PubMed ID: 33447827
[TBL] [Abstract][Full Text] [Related]
5. Author Correction: Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel‑related ovarian damage in mice.
Alalawy AI; Sakran M; Alzuaibr FM; Alotaibi MA; El-Hefnawy ME; Hazazi AY; El-Gendy SM; Aidy EA; Effat H; Ismail DF; Hessien M
Sci Rep; 2024 Apr; 14(1):9788. PubMed ID: 38684881
[No Abstract] [Full Text] [Related]
6. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT
Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Quinn JE; Kennedy RD; Mullan PB; Gilmore PM; Carty M; Johnston PG; Harkin DP
Cancer Res; 2003 Oct; 63(19):6221-8. PubMed ID: 14559807
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatics Analysis of Expression and Alterations of BARD1 in Breast Cancer.
Chen YZ; Zuo D; Ren HL; Fan SJ; Ying G
Technol Cancer Res Treat; 2019; 18():1533033819892260. PubMed ID: 31808361
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
Du ZH; Bi FF; Wang L; Yang Q
Mol Genet Genomic Med; 2018 May; 6(4):638-47. PubMed ID: 29797793
[TBL] [Abstract][Full Text] [Related]
11. hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1.
He X; Fan S
Oncol Rep; 2018 Mar; 39(3):977-984. PubMed ID: 29286157
[TBL] [Abstract][Full Text] [Related]
12. Management of hereditary breast and ovarian cancer.
Yamauchi H; Takei J
Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
[TBL] [Abstract][Full Text] [Related]
13. Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
Wang Y; Ung MH; Cantor S; Cheng C
Sci Rep; 2017 Nov; 7(1):15742. PubMed ID: 29146938
[TBL] [Abstract][Full Text] [Related]
14. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
Hollis RL; Churchman M; Gourley C
Onco Targets Ther; 2017; 10():2539-2551. PubMed ID: 28546758
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
16. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
Young A; Berry R; Holloway AF; Blackburn NB; Dickinson JL; Skala M; Phillips JL; Brettingham-Moore KH
BMC Cancer; 2014 Nov; 14():808. PubMed ID: 25369795
[TBL] [Abstract][Full Text] [Related]
17. A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.
Kononenko AV; Bansal R; Lee NC; Grimes BR; Masumoto H; Earnshaw WC; Larionov V; Kouprina N
Nucleic Acids Res; 2014 Dec; 42(21):e164. PubMed ID: 25260588
[TBL] [Abstract][Full Text] [Related]
18. DNA-PKcs activates the Chk2-Brca1 pathway during mitosis to ensure chromosomal stability.
Shang Z; Yu L; Lin YF; Matsunaga S; Shen CY; Chen BP
Oncogenesis; 2014 Feb; 3(2):e85. PubMed ID: 24492479
[TBL] [Abstract][Full Text] [Related]
19. Transformation of human ovarian surface epithelial cells by Krüppel-like factor 8.
Lu H; Wang X; Urvalek AM; Li T; Xie H; Yu L; Zhao J
Oncogene; 2014 Jan; 33(1):10-8. PubMed ID: 23222713
[TBL] [Abstract][Full Text] [Related]
20. BRCAness: finding the Achilles heel in ovarian cancer.
Rigakos G; Razis E
Oncologist; 2012; 17(7):956-62. PubMed ID: 22673632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
